Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Harmony Biosciences Holdings, Inc. - Common Stock
(NQ:
HRMY
)
35.29
UNCHANGED
Streaming Delayed Price
Updated: 1:00 PM EST, Nov 28, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Harmony Biosciences Holdings, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Nasdaq Down Over 50 Points; US Goods Trade Deficit Widens Slightly
↗
March 28, 2023
U.S. stocks traded mixed this morning, with the Nasdaq Composite dropping around 50 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.01% to 32,436.22 while the NASDAQ fell...
Via
Benzinga
Short Seller Report On Harmony Biosciences: Here's Why The Stock Is Tanking
↗
March 28, 2023
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) shares are trading lower after Scorpion Capital filed a Citizen's Petition with the FDA requesting the withdrawal of approval of Wakix (pitolisant).
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
March 28, 2023
Via
Benzinga
7 Healthcare Stocks to Buy for Long-Term Growth and Stability
↗
March 21, 2023
These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio as we get deeper into 2023.
Via
InvestorPlace
The Latest Analyst Ratings for Harmony Biosciences
↗
February 22, 2023
Via
Benzinga
With This Big Transition Ahead, Is Novavax a Buy?
↗
January 12, 2023
Novavax stock sank 92% last year.
Via
The Motley Fool
4 Analysts Have This to Say About Harmony Biosciences
↗
November 03, 2022
Within the last quarter, Harmony Biosciences (NASDAQ:HRMY) has observed the following analyst ratings:
Via
Benzinga
Harmony Biosciences (HRMY) Q4 2022 Earnings Call Transcript
↗
February 21, 2023
HRMY earnings call for the period ending December 31, 2022.
Via
The Motley Fool
Harmony Biosciences, The No. 3 Biotech, Just Topped Forecasts; But Concerns Persist
↗
February 21, 2023
The company offered neither financial guidance nor plans for a new CEO.
Via
Investor's Business Daily
Big Retailers Report
↗
February 21, 2023
Good Morning Everyone! Customers are setting banks on fire in Lebanon because they can’t get their money out. Inflation is at +170%. This is what a currency collapse looks like:
Via
Benzinga
Harmony Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
February 21, 2023
From
Harmony Biosciences
Via
GlobeNewswire
Alkermes Stock Sees Rising Relative Price Strength
↗
February 17, 2023
The Relative Strength (RS) Rating for Alkermes stock entered a new percentile Friday, with an increase from 79 to 86.
Via
Investor's Business Daily
Anavex Life Sciences Stock Shows Improved Price Strength Rating
↗
February 07, 2023
Anavex Life Sciences stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 75.
Via
Investor's Business Daily
The 7 Best Biotech Stocks to Buy for February 2023
↗
February 07, 2023
Following the wave of red ink last year, astute investors should target the best biotech stocks to buy this month for strong growth potential.
Via
InvestorPlace
7 Healthcare Stocks That Will Be Big Winners in 2023
↗
January 31, 2023
Healthcare stocks had a strong 2022 which will continue throughout 2023 making these picks ones to consider.
Via
InvestorPlace
If You Invested $1,000 in Novavax In 2020, This Is How Much You Would Have Today
↗
January 13, 2023
The stock has gone on a wild ride over the past few years.
Via
The Motley Fool
2 Biotechs Making Waves With A Single Product in their Pipeline
January 11, 2023
Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise.
Via
MarketBeat
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
January 09, 2023
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.
Via
Benzinga
NVAX Stock Alert: What to Know as Novavax Names New CEO
↗
January 09, 2023
Although a change at the top boosted sentiment for Novavax, the harsh reality is that NVAX stock faces a mountain of worries.
Via
InvestorPlace
Moderna Stock Shows Surprising Strength; Key Rating Upgraded
↗
December 14, 2022
See if Moderna stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day average.
Via
Investor's Business Daily
BeiGene Stock Shows Market Leadership With Jump To 82 RS Rating
↗
December 08, 2022
On Thursday, China-based BeiGene stock cleared that desired 80-plus benchmark, with a jump to 82 from 77 a day earlier.
Via
Investor's Business Daily
Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
↗
November 29, 2022
Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 92 Tuesday, up from 89 a day earlier.
Via
Investor's Business Daily
BioCryst Pharmaceuticals Stock Sees RS Rating Rise To 84
↗
November 11, 2022
The Relative Strength (RS) Rating for BioCryst Pharmaceuticals stock climbed into a new percentile Friday, with a rise from 64 to 84.
Via
Investor's Business Daily
Looking Into Harmony Biosciences's Return On Capital Employed
↗
November 09, 2022
According to Benzinga Pro, during Q3, Harmony Biosciences (NASDAQ:HRMY) earned $87.94 million, a 273.73% increase from the preceding quarter. Harmony Biosciences also posted a total of $117.21 million...
Via
Benzinga
Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday
↗
November 02, 2022
Gainers
Via
Benzinga
Gartner, Sony, Uber And Other Big Gainers From Tuesday
↗
November 02, 2022
U.S. stocks closed lower on Tuesday, with the Nasdaq Composite dropping around 100 points. Here is the list of some big stocks recording gains in the previous session.
Via
Benzinga
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2022 Earnings Call Transcript
↗
November 01, 2022
HRMY earnings call for the period ending September 30, 2022.
Via
The Motley Fool
Why IBD 50 Stock Harmony Biosciences Flew To The High End Of Its Buy Zone
↗
November 01, 2022
The third-quarter beat, alone, wasn't enough to drive the positive stock movement.
Via
Investor's Business Daily
Recap: Harmony Biosciences Q3 Earnings
↗
November 01, 2022
Harmony Biosciences (NASDAQ:HRMY) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings Harmony Biosciences...
Via
Benzinga
Harmony Biosciences Reports Third Quarter 2022 Financial Results and Business Updates
November 01, 2022
From
Harmony Biosciences
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today